Research programme: autoimmune therapeutics - Scripps Research Institute

Drug Profile

Research programme: autoimmune therapeutics - Scripps Research Institute

Alternative Names: SR 1001

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Scripps Clinic
  • Class Small molecules
  • Mechanism of Action Retinoic acid receptor alpha antagonists; Retinoic acid receptor gamma antagonists; Th17 cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
  • 18 Apr 2011 Preclinical trials in Multiple sclerosis in USA (unspecified route)
  • 18 Apr 2011 Research programme: autoimmune therapeutics - Scripps Research Institute is available for licensing. http://www.scripps.edu
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top